听力与言语-语言病理学

行为科学

医学伦理学

你正在浏览CANCER BIOLOGY & THERAPY期刊下所有文献
  • CXCL4 mediates tumor regrowth after chemotherapy by suppression of antitumor immunity.

    abstract::The recurrence of colorectal cancer after chemotherapy is the leading cause of its high mortality. We propose that elucidating the mechanisms of tumor regrowth after chemotherapy in tumor-bearing mice may provide new insights into tumor relapse in cancer patients. We firstly report the identification of a chemokine, C...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1095404

    authors: Zhang Y,Gao J,Wang X,Deng S,Ye H,Guan W,Wu M,Zhu S,Yu Y,Han W

    更新日期:2015-01-01 00:00:00

  • Small molecule inhibitors of IRES-mediated translation.

    abstract::Many genes controlling cell proliferation and survival (those most important to cancer biology) are now known to be regulated specifically at the translational (RNA to protein) level. The internal ribosome entry site (IRES) provides a mechanism by which the translational efficiency of an individual or group of mRNAs c...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1071729

    authors: Vaklavas C,Meng Z,Choi H,Grizzle WE,Zinn KR,Blume SW

    更新日期:2015-01-01 00:00:00

  • Harmine suppresses homologous recombination repair and inhibits proliferation of hepatoma cells.

    abstract::To avoid cell cycle arrest or apoptosis, rapidly proliferating cancer cells have to promote DNA double strand break (DSB) repair to fix replication stress induced DSBs. Therefore, developing drugs blocking homologous recombination (HR) and nonhomologous end joining (NHEJ) - 2 major DSB repair pathways - holds great po...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1078021

    authors: Zhang L,Zhang F,Zhang W,Chen L,Gao N,Men Y,Xu X,Jiang Y

    更新日期:2015-01-01 00:00:00

  • Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.

    abstract::Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase that has mainly been studied in haematopoietic cells. We have investigated whether BTK is a potential therapeutic target in prostate cancer. We find that BTK is expressed in prostate cells, with the alternate BTK-C isoform predominantly expressed in pros...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1078023

    authors: Kokabee L,Wang X,Sevinsky CJ,Wang WL,Cheu L,Chittur SV,Karimipoor M,Tenniswood M,Conklin DS

    更新日期:2015-01-01 00:00:00

  • Hes1: a key role in stemness, metastasis and multidrug resistance.

    abstract::Hes1 is one mammalian counterpart of the Hairy and Enhancer of split proteins that play a critical role in many physiological processes including cellular differentiation, cell cycle arrest, apoptosis and self-renewal ability. Recent studies have shown that Hes1 functions in the maintenance of cancer stem cells (CSCs)...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.1080/15384047.2015.1016662

    authors: Liu ZH,Dai XM,Du B

    更新日期:2015-01-01 00:00:00

  • Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study.

    abstract::The surprising results published by FIRE-3 revealed that the overall survival (OS) of RAS wild-type metastatic colorectal cancer (mCRC) patients treated with Cetuximab(Cmab) and FOLFIRI combination was prolonged to 33.1 months. The substantial increase in testing and treatment costs, however, impose a considerable hea...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1095398

    authors: Wen F,Yang Y,Zhang P,Zhang J,Zhou J,Tang R,Chen H,Zheng H,Fu P,Li Q

    更新日期:2015-01-01 00:00:00

  • FBXO4 loss facilitates carcinogen induced papilloma development in mice.

    abstract::Cyclin D1 is frequently overexpressed in esophageal squamous cell carcinoma (ESCC) and is considered a key driver of this disease. Mutations in FBXO4, F-box specificity factor that directs SCF-mediated ubiquitylation of cyclin D1, occur in ESCC with concurrent overexpression of cyclin D1 suggesting a potential tumor s...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1026512

    authors: Lian Z,Lee EK,Bass AJ,Wong KK,Klein-Szanto AJ,Rustgi AK,Diehl JA

    更新日期:2015-01-01 00:00:00

  • MiR-101 inhibits cell growth and tumorigenesis of Helicobacter pylori related gastric cancer by repression of SOCS2.

    abstract::Several microRNAs (miRNA) have been implicated in H. pylori related gastric cancer (GC). However, the molecular mechanism of miRNAs in gastric cancer has not been fully understood. In this study, we reported that miR-101 is significantly down-regulated in H. pylori positive tissues and cells and in tumor tissues with ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/15384047.2014.987523

    authors: Zhou X,Xia Y,Li L,Zhang G

    更新日期:2015-01-01 00:00:00

  • c-Myc modulation: a key role in melanoma drug response.

    abstract::Understanding molecular mechanisms involved in melanoma resistance to drugs is a big challenge. Experimental evidences suggested a correlation between mutational status in B-RAF and melanoma cell susceptibility to drugs, such as paclitaxel, doxorubicin and temozolomide, which generate an accumulation of hydrogen perox...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1030546

    authors: Fico A,Alfano D,Valentino A,Vasta V,Cavalcanti E,Travali S,Patriarca EJ,Caputo E

    更新日期:2015-01-01 00:00:00

  • Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells.

    abstract::Oncolytic viruses have recently received widespread attention for their potential in innovative cancer therapy. Many telomerase promoter-regulated oncolytic adenoviral vectors retain E1A and E1B. However, the functions of E1A and E1B proteins in the oncolytic role of replication-competent adenovirus (RCAd) and RCAd en...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.29842

    authors: Wei F,Wang H,Chen X,Li C,Huang Q

    更新日期:2014-10-01 00:00:00

  • Production of IL-1β by bone marrow-derived macrophages in response to chemotherapeutic drugs: synergistic effects of doxorubicin and vincristine.

    abstract::Cytotoxic chemotherapeutic drugs, especially when used in combination, are widely employed to treat a variety of cancers in patients but often lead to serious symptoms that negatively affect physical functioning and quality of life. There is compelling evidence that implicates cytotoxic chemotherapy-induced inflammati...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.29922

    authors: Wong J,Tran LT,Magun EA,Magun BE,Wood LJ

    更新日期:2014-10-01 00:00:00

  • Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.

    abstract::Numerous tyrosine kinase inhibitors (TKIs) targeting c-Met are currently in clinical trials for several cancers. Their efficacy is limited due to the development of resistance. The present study aims to elucidate this mechanism of c-Met TKI resistance by investigating key mTOR and Wnt signaling proteins in melanoma ce...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.29451

    authors: Etnyre D,Stone AL,Fong JT,Jacobs RJ,Uppada SB,Botting GM,Rajanna S,Moravec DN,Shambannagari MR,Crees Z,Girard J,Bertram C,Puri N

    更新日期:2014-09-01 00:00:00

  • Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells.

    abstract::The synergistic effect of combined drug therapy provides an enhanced treatment for advanced liver cancer. We aimed to investigate the underlying mechanism of cetuximab sensitization by rapamycin in hepatoma cells. Four hepatoma cell lines, HepG2, HuH7, SNU-387, and SNU-449, were treated with cetuximab or cetuximab plu...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.29113

    authors: Chen W,Hu QD,Xia XF,Liang C,Liu H,Zhang Q,Ma T,Liang F,Liang TB

    更新日期:2014-08-01 00:00:00

  • Doxorubicin and 5-fluorouracil induced accumulation and transcriptional activity of p53 are independent of the phosphorylation at serine 15 in MCF-7 breast cancer cells.

    abstract::The chemotherapeutic agents doxorubicin (dox) or 5-fluorouracil (5FU) are used to treat cancer cells as they cause irreparable DNA damage, inducing these aberrant cells to undergo cell death. The mediator of this process is presumed to be in part the tumor suppressor p53 which regulates genes involved in DNA repair an...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.29112

    authors: Balmer MT,Katz RD,Liao S,Goodwine JS,Gal S

    更新日期:2014-08-01 00:00:00

  • Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer.

    abstract::TRA-8, a monoclonal antibody targeting death receptor, has demonstrated high therapeutic effect for triple negative breast cancer (TNBC) in preclinical models. Tamoxifen, the standard of care for ERα-positive breast cancer, induces apoptosis via ERβ, which commonly presents in TNBC cells. The current study investigate...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.29183

    authors: Kim H,Samuel SL,Zhai G,Rana S,Taylor M,Umphrey HR,Oelschlager DK,Buchsbaum DJ,Zinn KR

    更新日期:2014-08-01 00:00:00

  • Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.

    abstract::KRAS mutational status has been shown to be a predictive biomarker of resistance to anti-EGFR monoclonal antibody (mAb) therapy in patients with metastatic colorectal cancer. We report the spectrum of KRAS mutation in 1506 patients with colorectal cancer and the identification and characterization of rare insertion mu...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.28550

    authors: Tong JH,Lung RW,Sin FM,Law PP,Kang W,Chan AW,Ma BB,Mak TW,Ng SS,To KF

    更新日期:2014-06-01 00:00:00

  • Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer.

    abstract::The hypothesis of the "liquid biopsy" using circulating tumor cells (CTCs) emerged as a minimally invasive alternative to traditional tissue biopsy to determine cancer therapy. Discordance for biomarkers expression between primary tumor tissue and circulating tumor cells (CTCs) has been widely reported, thus rendering...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.28020

    authors: Raimondi C,Nicolazzo C,Gradilone A,Giannini G,De Falco E,Chimenti I,Varriale E,Hauch S,Plappert L,Cortesi E,Gazzaniga P

    更新日期:2014-05-01 00:00:00

  • Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.

    abstract::Several agents targeting the epidermal growth factor receptor (EGFR) have been FDA-approved to treat cancer patients with varying tumor types including metastatic colorectal cancer. Many patients treated with anti-EGFR therapy however do not respond and those that do initially respond often acquire resistance. Here we...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.28179

    authors: Ung N,Putoczki TL,Stylli SS,Ng I,Mariadason JM,Chan TA,Zhu HJ,Luwor RB

    更新日期:2014-05-01 00:00:00

  • Tumor cells and memory T cells converge at glycolysis: therapeutic implications.

    abstract::In the immune system, activation of naïve T (Tn) cells into effector T cells (Teff) involves a metabolic switch to glycolysis to promote rapid proliferation and differentiation. In the October issue of The Journal of Clinical Investigation, Sukumar et al. have demonstrated that in CD8(+) memory T (Tems) cells glycolyt...

    journal_title:Cancer biology & therapy

    pub_type: 评论,杂志文章

    doi:10.4161/cbt.28160

    authors: Karthikeyan S,Geschwind JF,Ganapathy-Kanniappan S

    更新日期:2014-05-01 00:00:00

  • The status of zinc in the development of hepatocellular cancer: an important, but neglected, clinically established relationship.

    abstract::Liver cancer (hepatocellular carcinoma, HCC) is increasing worldwide. About 75% of HCC cases result in death generally within one year. The factors responsible for the initiation and progression of HCC remain largely unknown and speculative, thereby impeding advancements in the development of effective therapeutic age...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.27633

    authors: Costello LC,Franklin RB

    更新日期:2014-04-01 00:00:00

  • All-trans-retinoic acid antagonizes the Hedgehog pathway by inducing patched.

    abstract::Male germ cell tumors (GCTs) are a model for a curable solid tumor. GCTs can differentiate into mature teratomas. Embryonal carcinomas (ECs) represent the stem cell compartment of GCTs and are the malignant counterpart to embryonic stem (ES) cells. GCTs and EC cells are useful to investigate differentiation therapy an...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.27821

    authors: Busch AM,Galimberti F,Nehls KE,Roengvoraphoj M,Sekula D,Li B,Guo Y,Direnzo J,Fiering SN,Spinella MJ,Robbins DJ,Memoli VA,Freemantle SJ,Dmitrovsky E

    更新日期:2014-04-01 00:00:00

  • MicroRNA expression signatures of stage, grade, and progression in clear cell RCC.

    abstract::Clear cell RCC is the most common, and more likely to metastasize, of the three main histological types of RCC. Pathologic stage is the most important prognostic indicator and nuclear grade can predict outcome within stages of localized RCC. Epithelial tumors are thought to accumulate a series of genetic and epigeneti...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.27314

    authors: Gowrishankar B,Ibragimova I,Zhou Y,Slifker MJ,Devarajan K,Al-Saleem T,Uzzo RG,Cairns P

    更新日期:2014-03-01 00:00:00

  • TMPRSS4 correlates with colorectal cancer pathological stage and regulates cell proliferation and self-renewal ability.

    abstract::Transmembrane protease/serine 4 (TMPRSS4) is a member of the type II transmembrane serine protease (TTSP) family and it was found highly expressed in several cancers. This study aims to evaluate the expression of TMPRSS4 in colorectal cancer (CRC) and investigate its role in proliferation and self-renewal of colon can...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.27308

    authors: Huang A,Zhou H,Zhao H,Quan Y,Feng B,Zheng M

    更新日期:2014-03-01 00:00:00

  • Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.

    abstract::Imatinib, an ABL tyrosine kinase inhibitor (TKI), has shown clinical efficacy against chronic myeloid leukemia (CML). However, a substantial number of patients develop resistance to imatinib treatment due to the emergence of clones carrying mutations in the protein BCR-ABL. The phosphoinositide 3 kinase (PI3K)/Akt/mam...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.26725

    authors: Okabe S,Tauchi T,Tanaka Y,Kitahara T,Kimura S,Maekawa T,Ohyashiki K

    更新日期:2014-02-01 00:00:00

  • DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.

    abstract::Current treatment modalities for pancreatic carcinoma afford only modest survival benefits. TRAIL, as a potent and specific inducer of apoptosis in cancer cells, would be a promising new treatment option. However, since not all pancreatic cancer cells respond to TRAIL, further improvements and optimizations are still ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/15384047.2014.972183

    authors: Yu R,Albarenque SM,Cool RH,Quax WJ,Mohr A,Zwacka RM

    更新日期:2014-01-01 00:00:00

  • Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.

    abstract::Adverse events in platinum-based chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) are major challenges. In this study, we investigated the role of the p53 and MDM2 genes in predicting adverse events in NSCLC patients treated with platinum-based chemotherapy. Specifically, we examined the p53 ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/15384047.2014.956599

    authors: Zheng D,Chen Y,Gao C,Wei Y,Cao G,Lu N,Hou Y,Jiang X,Wang J

    更新日期:2014-01-01 00:00:00

  • Targeting of two aspects of metabolism in breast cancer treatment.

    abstract::Deregulated metabolism is gaining recognition as a hallmark of cancer cells, and is being explored for therapeutic potential. The Warburg effect is a metabolic phenotype that occurs in 90% of tumors, where glycolysis is favored despite the presence of oxygen. Dichloroacetate (DCA) is a pyruvate dehydrogenase kinase (P...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/15384047.2014.955992

    authors: Gang BP,Dilda PJ,Hogg PJ,Blackburn AC

    更新日期:2014-01-01 00:00:00

  • 5-hydroxymethylcytosine: a new insight into epigenetics in cancer.

    abstract::DNA methylation at the 5 position of cytosine (5-mC) has emerged as a key epigenetic marker that plays essential roles in various biological and pathological processes. 5-mC can be converted to 5-hydroxymethylcytosine (5-hmC) by the ten-eleven translocation (TET) family proteins, which is now widely recognized as the ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.27144

    authors: Ye C,Li L

    更新日期:2014-01-01 00:00:00

  • Binding and inhibition of drug transport proteins by heparin: a potential drug transporter modulator capable of reducing multidrug resistance in human cancer cells.

    abstract::A major problem in cancer treatment is the development of resistance to chemotherapeutic agents, multidrug resistance (MDR), associated with increased activity of transmembrane drug transporter proteins which impair cytotoxic treatment by rapidly removing the drugs from the targeted cells. Previously, it has been show...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.27148

    authors: Chen Y,Scully M,Petralia G,Kakkar A

    更新日期:2014-01-01 00:00:00

  • Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.

    abstract::Mcl-1, a pro-survival member of the Bcl-2 protein family, is an attractive target for cancer therapy. We have recently identified the natural product marinopyrrole A (maritoclax) as a novel small molecule Mcl-1 inhibitor. Here, we describe the structure-activity relationship study of pyoluteorin derivatives based on m...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/15384047.2014.972799

    authors: Doi K,Gowda K,Liu Q,Lin JM,Sung SS,Dower C,Claxton D,Loughran TP Jr,Amin S,Wang HG

    更新日期:2014-01-01 00:00:00

  • mRNA expression profile of multidrug-resistant genes in acute lymphoblastic leukemia of children, a prognostic value for ABCA3 and ABCA2.

    abstract::Multidrug resistance (MDR) is an important cause of treatment failure in acute lymphoblastic leukemia (ALL). The ABC family of membrane transporters is proposed, albeit with controversy, to be involved in this process. The present study aims to investigate the mRNA expression profile of several genes of this family, i...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.26603

    authors: Rahgozar S,Moafi A,Abedi M,Entezar-E-Ghaem M,Moshtaghian J,Ghaedi K,Esmaeili A,Montazeri F

    更新日期:2014-01-01 00:00:00

  • Cancer mortality trends between 1988 and 2009 in the metropolitan area of Naples and Caserta, Southern Italy: Results from a joinpoint regression analysis.

    abstract::Mortality data by geographic area and trend-based surveillance are particularly relevant in orienting public health decisions targeting specific populations. We analyzed overall and site-specific cancer mortality between 1988 and 2009 in the metropolitan area of Naples and Caserta in southern Italy. Age-standardized m...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.26425

    authors: Crispo A,Barba M,Malvezzi M,Arpino G,Grimaldi M,Rosso T,Esposito E,Sergi D,Ciliberto G,Giordano A,Montella M

    更新日期:2013-12-01 00:00:00

  • Mitogen-activated protein kinase phosphatase-1 inhibition and sustained extracellular signal-regulated kinase 1/2 activation in camptothecin-induced human colon cancer cell death.

    abstract::Camptothecins are commonly used chemotherapeutics; in some models, they enhance signaling via the mitogen-activated protein kinase (MAPK) pathway through effects on upstream kinases. To evaluate the impact of camptothecin (CPT) on MAPKs in human colon cancer, we studied HCT116 and CaCo2 colon cancer cells. We found th...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.26044

    authors: Lee M,Young Kim S,Kim J,Kim HS,Kim SM,Kim EJ

    更新日期:2013-11-01 00:00:00

  • The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.

    abstract::Because of its high mortality rate, ovarian cancer is a leading cause of death among women and a highly unmet medical need. New therapeutic agents that are effective and well tolerated are needed and cancer antigen-specific monoclonal antibodies that have direct pharmacologic effects or can stimulate immunological res...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.26106

    authors: Lin J,Spidel JL,Maddage CJ,Rybinski KA,Kennedy RP,Krauthauser CL,Park YC,Albone EF,Jacob S,Goserud MT,Martinez BP,Chao Q,Zhou Y,Nicolaides NC,Kline JB,Grasso L

    更新日期:2013-11-01 00:00:00

  • Daunomycin, an antitumor DNA intercalator, influences histone-DNA interactions.

    abstract::Although daunomycin and adriamycin are considered effective antitumor drugs and have been used in the clinic for over 40 years, their mechanism of action is still a matter of debate. We investigated the influence of daunomycin on interaction between linker or core histones and DNA in live HeLa cells in vitro, using im...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.25328

    authors: Wójcik K,Zarębski M,Cossarizza A,Dobrucki JW

    更新日期:2013-09-01 00:00:00

  • Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer.

    abstract::E2F-1, a key transcription factor necessary for cell growth, DNA repair, and differentiation, is an attractive target for development of anticancer drugs in tumors that are E2F "oncogene addicted". We identified a peptide isolated from phage clones that bound tightly to the E2F-1 promoter consensus sequence. The pepti...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.25184

    authors: Xie X,Kerrigan JE,Minko T,Garbuzenko O,Lee KC,Scarborough A,Abali EE,Budak-Alpdogan T,Johnson-Farley N,Banerjee D,Scotto KW,Bertino JR

    更新日期:2013-08-01 00:00:00

  • Exposure to estrogen and ionizing radiation causes epigenetic dysregulation, activation of mitogen-activated protein kinase pathways, and genome instability in the mammary gland of ACI rats.

    abstract::The impact of environmental mutagens and carcinogens on the mammary gland has recently received a lot of attention. Among the most generally accepted carcinogenic agents identified as factors that may increase breast cancer incidence are ionizing radiation and elevated estrogen levels. However, the molecular mechanism...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.24599

    authors: Kutanzi K,Kovalchuk O

    更新日期:2013-07-01 00:00:00

  • Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab.

    abstract::The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in human cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been approved for use in oncology. Despite clinical success the majority of patients do not respond to cetuximab and those who initially respond frequently ac...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.24342

    authors: Iida M,Brand TM,Campbell DA,Starr MM,Luthar N,Traynor AM,Wheeler DL

    更新日期:2013-06-01 00:00:00

  • Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial.

    abstract:OBJECTIVES:To evaluate the 6-mo overall survival, safety and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer. METHODS:Eligibility included: previously untreated metastatic adenocarcinoma of the pancreas with metastases incurab...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,多中心研究

    doi:10.4161/cbt.23625

    authors: Infante JR,Arkenau HT,Bendell JC,Rubin MS,Waterhouse D,Jones GT,Spigel DR,Lane CM,Hainsworth JD,Burris HA 3rd

    更新日期:2013-04-01 00:00:00

  • Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention.

    abstract::The early observations by Dr Otto Warburg revealed that fundamentally metabolic differences exist between malignant tumor cells and adjacent normal cells. Many studies have further reported the relationship between altered cellular metabolism and therapeutic outcomes. These observations suggest that targeting the pecu...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.22958

    authors: Zhang Y,Yang JM

    更新日期:2013-02-01 00:00:00

335 条记录 3/9 页 « 123456789 »